Fig. 5From: KRAS mutation effects on the 2-[18F]FDG PET uptake of colorectal adenocarcinoma metastases in the liverLogistic regression curves based on all 60 lesions for SUVMAX without any corrections (a), with both PVE and uptake time corrections (b), and for SURMAX with both corrections (c), when KRAS gene amplification is grouped with wild-type mutations. Dark gray shaded areas represent the 95% confidence intervals around the probability values. Individual data points are shown with dots at probability levels of 0.00 and 1.00Back to article page